Assessment of response to treatment of unresectable liver tumours with 90Y microspheres: Value of FDG PET versus computed tomography
- 1 January 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Nuclear Medicine Communications
- Vol. 28 (1), 15-20
- https://doi.org/10.1097/mnm.0b013e328011453b
Abstract
Introduction Selective internal radiation therapy (SIRT) with SIR spheres (90Y microspheres) is a treatment option for liver tumours in patients in whom other therapies are inappropriate or have failed. This study aims to assess the value of FDG PET in assessing the response to SIRT as compared to computed tomography (CT). Material and methods Twenty-one patients (11 F, 10 M; age range 40–75 years, mean, 58 years) received SIR spheres at the Hammersmith Hospital. One patient received two treatments. Most patients had colorectal metastases (n=10), while the others (n=11) had liver metastasis from different primaries. The mean administered dose was 1.9 GBq (range, 1.2–2.5 GBq). Follow-up was done with FDG PET and CT at 6 weeks, and 6-monthly thereafter. Pre-therapy and post-therapy CT and PET scans were assessed visually (RECIST criteria for CT) and semi-quantitative for PET using the standardized uptake value (SUV). Result Eighty-six percent of patients showed decreased PET activity at 6 weeks while only 13% showed a partial response in the size of tumour on CT scan. The mean pre-treatment SUV was 12.2±3.7 and the mean post-treatment SUV was 9.3±3.7 (P=0.01). CT imaging showed progressive disease in 27% patients and stable liver disease in 60% patients. Based on FDG PET results one patient had surgery for down-staged tumour. Conclusion FDG PET imaging is more sensitive than CT in the assessment of early response to SIR spheres, allowing clinicians to proceed with further therapeutic options.Keywords
This publication has 11 references indexed in Scilit:
- Yttrium-90 Microsphere Therapy for Hepatic Malignancy: Devices, Indications, Technical Considerations, and Potential ComplicationsRadioGraphics, 2005
- Reduction of Metastatic Load to Liver after Intraarterial Hepatic Yttrium-90 Radioembolization as Evaluated by [18F]Fluorodeoxyglucose Positron Emission Tomographic ImagingJournal of Vascular and Interventional Radiology, 2005
- Selective Internal Radiation Therapy with SIR-Spheres® in Patients with Nonresectable Liver TumorsCancer Biotherapy & Radiopharmaceuticals, 2005
- 90Y microsphere treatment of unresectable liver metastases: changes in 18F-FDG uptake and tumour size on PET/CTEuropean Journal of Nuclear Medicine and Molecular Imaging, 2005
- Randomised phase 2 trial of SIR‐Spheres® plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancerJournal of Surgical Oncology, 2004
- Evaluating 90Y-glass microsphere treatment response of unresectable colorectal liver metastases by [18F]FDG PET: a comparison with CT or MRIEuropean Journal of Nuclear Medicine and Molecular Imaging, 2002
- Randomised trial of SIR-Spheres® plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancerAnnals of Oncology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings.Radiology, 1993
- The blood supply of colorectal liver metastasesBritish Journal of Cancer, 1978